Comment on : 'Distribution, phenotypic characterisation and antibiogram of bacterial species from hospital environment in Nigeria: Public health implications'

Yıl 2019, Cilt: 4 Sayı: 2, 32 - 33, 30.06.2019

Hasan Cenk Mirza

Öz

Sir,

I read with
interest the article by Onuoha et al. entitled 'Distribution, phenotypic
characterisation and antibiogram of bacterial species from hospital environment
in Nigeria: Public health implications'. The authors performed antimicrobial susceptibility
testing for the bacteria that were isolated from various surfaces of a federal
teaching hospital. The authors used disk diffusion method for the detection of
vancomycin resistance among S. aureus
isolates. According to current guidelines, the disk diffusion test with
vancomycin is unreliable and should not be used for the detection of vancomycin
resistance in S. aureus. Clinical and
Laboratory standards Institute (CLSI) and European
Committee on Antimicrobial Susceptibility Testing (EUCAST) recommend vancomycin
MIC testing to determine the susceptibility of staphylococci to vancomycin.

The authors also performed antimicrobial susceptibility
testing for Salmonella spp. and Shigella spp. isolates. They included cephalothin
(a first generation cephalosporin), cefuroxime (a second generation
cephalosporin), streptomycin and gentamicin (aminoglycosides) among the
antimicrobial agents tested against the isolates of Salmonella spp. and Shigella
spp. According to CLSI guidelines, first and second generation cephalosporins,
cephamycins and aminoglycosides may appear active in vitro, but these agents
are clinically ineffective and shouldn't be reported as susceptible.

Anahtar Kelimeler

Antimicrobial susceptibility testing, S. aureus, vancomycin, Salmonella, Shigella

Kaynakça

• 1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-eighth Informational Supplement M100-S28, Wayne, PA (USA), 2018.
• 2. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 9.0 http://www.eucast.org/clinical_breakpoints/ (March 2019, date last accessed)
• 3. Mirza HC. Glycopeptide resistance in S. aureus. In: Enany S, Alexander LE, eds. The rise of virulence and antibiotic resistance in Staphylococcus aureus. Croatia: InTech; 2017. p. 43-59.
• 4. Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014; 124(7): 2836-40.